the invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of nr2b subunit selective nmda antagonists . the disorders that can be treating by the invention include hearing loss , vision loss , neurodegeneration caused by epileptic seizures , neurotoxin poisoning , restless leg syndrome , multi - system atrophy , non - vascular headache , and depression .